J 2022

Přímé a nepříme dopady pandemie COVID-19 na pacienty s nádory plic a pleury - retrospetivní analýza dat pacientů léčených na Klinice nemocí plicních a tuberkulózy FN Brno v době 2. a 3. koronavirové vlny

BRATOVÁ, Monika; Kristián BRAT a Lenka JAKUBÍKOVÁ

Základní údaje

Originální název

Přímé a nepříme dopady pandemie COVID-19 na pacienty s nádory plic a pleury - retrospetivní analýza dat pacientů léčených na Klinice nemocí plicních a tuberkulózy FN Brno v době 2. a 3. koronavirové vlny

Název anglicky

Direct and indirect impacts of the COVID-19 pandemic on patients with pulmonary and pleural malignancies – a retrospective analysis of patient outcomes treated at Department of Respiratory Diseases, University Hospital Brno, during the 2nd and 3rd corona

Autoři

Vydání

Klinická onkologie, Praha, Česká lékařská společnost J. E. Purkyně, 2022, 0862-495X

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00126441

Organizační jednotka

Lékařská fakulta

DOI

EID Scopus

Klíčová slova česky

COVID-19; impact on health; lung cancer; mesothelioma

Klíčová slova anglicky

COVID-19; impact on health; lung cancer; mesothelioma

Štítky

Příznaky

Recenzováno
Změněno: 8. 2. 2023 12:35, Mgr. Tereza Miškechová

Anotace

ORIG EN

V originále

Background: The pandemic of COVID-19 has significantly influenced the diagnostics and treatment of patients with lung and pleural malignancies. This group of patients is the riskiest, compared to patients with other cancers, both in morbidity and mortality. Study population and methods: The data of patients with lung/pleural malignancies and proved COVID-19 positivity were analyzed at the Department of Respiratory Diseases and Tuberculosis, University Hospital Brno, during the period from October 2020 to May 2021. Demographic data, information about the course of SARS-CoV-2 infection and oncological disease as well as mortality were monitored. Together with the data from the study population, three case reports are also presented. Results: Fifty-three patients were found (79% males), mean age 69.4 years, mainly with adenocarcinoma histology. A total of 47.1% patients experienced mild course of SARS-CoV-2 infection, 56.6% needed hospitalization, 24.5% died. Active anticancer treatment was delayed in 62.4% cases due to SARS-CoV-2 infection; the mean time of the delay reached 14.5 days. Conclusion: Patients with lung and pleural malignancies have a high risk of severe course of SARS-CoV-2 infection and mortality. Moreover, the ongoing SARS-CoV-2 infection as well as postcovid changes can complicate the anticancer treatment itself. © 2022, Czech Medical Association J.E. Purkyne. All rights reserved.

Anglicky

Background: The pandemic of COVID-19 has significantly influenced the diagnostics and treatment of patients with lung and pleural malignancies. This group of patients is the riskiest, compared to patients with other cancers, both in morbidity and mortality. Study population and methods: The data of patients with lung/pleural malignancies and proved COVID-19 positivity were analyzed at the Department of Respiratory Diseases and Tuberculosis, University Hospital Brno, during the period from October 2020 to May 2021. Demographic data, information about the course of SARS-CoV-2 infection and oncological disease as well as mortality were monitored. Together with the data from the study population, three case reports are also presented. Results: Fifty-three patients were found (79% males), mean age 69.4 years, mainly with adenocarcinoma histology. A total of 47.1% patients experienced mild course of SARS-CoV-2 infection, 56.6% needed hospitalization, 24.5% died. Active anticancer treatment was delayed in 62.4% cases due to SARS-CoV-2 infection; the mean time of the delay reached 14.5 days. Conclusion: Patients with lung and pleural malignancies have a high risk of severe course of SARS-CoV-2 infection and mortality. Moreover, the ongoing SARS-CoV-2 infection as well as postcovid changes can complicate the anticancer treatment itself. © 2022, Czech Medical Association J.E. Purkyne. All rights reserved.